All In Biotech

Drug Trial Radar · NCT06103773

A Study of Single and Multiple Oral Doses of TollB-001

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses and to Evaluate the Food Effect of TollB-001

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Sep 28, 2023

Primary completion

Apr 7, 2025

Study completion Apr 7, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the safety and tolerability of TollB-001 following the administration of single or multiple oral doses in healthy adult subjects

Conditions

  • Rheumatoid Arthritis

Interventions

  • TollB-001 tabletsDrug

    TollB-001 treatment

  • TollB-001 placeboDrug

    TollB-001 Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Red blood cell count(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  2. hematocrit(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  3. hemoglobin(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  4. white blood cell count(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  5. whiteblood cell differential count(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  6. plateletcount(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  7. Alanine aminotransferase(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  8. aspartateaminotransferase(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  9. alkaline phosphatase(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  10. gamma-glutamyl transpeptidase(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  11. total bilirubin(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  12. direct bilirubin(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  13. blood ureanitrogen (or blood urea)(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  14. creatinine(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  15. glucose(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  16. total protein(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  17. creatine kinase(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  18. Activated partial thromboplastin time(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  19. prothrombin time(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  20. internationalnormalized ratio(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  21. fibrinogen(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  22. urine pH(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  23. urine specific gravity(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  24. urine glucose(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  25. urine protein(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  26. urobilinogen(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  27. urine bilirubin(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  28. urine leukocyte(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  29. urine ketone body(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  30. urine red blood cells(physiological parameter) by investigatorTime frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
  31. AE/SAE monitoring by ToxicityGrading Scale for Healthy Adults and Volunteers Enrolled in Preventative Vaccine Trials,2007 (70 FR 22664)Time frame: First dose up to last follow-up visit(for a maximum of 20 days)
  32. physical examination(physiological parameter) by investigatorTime frame: First dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 ,Day11,Day14or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit.
  33. blood pressure(systolic pressure and diastolic pressure)(physiological parameter) by investigatorTime frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  34. pulse(physiological parameter) by investigatorTime frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  35. respiratory rate(physiological parameter) by investigatorTime frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  36. body temperature(physiological parameter) by investigatorTime frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  37. 12-lead ECGsTime frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit.
  38. B-ultrasound(physiological parameter) by investigatorTime frame: For a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day14 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chengdu Fifth People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.